PERJETA and Herceptin are two HER2-targeted therapies. While they work together, each treatment is designed to block a different part of the HER2 receptor to stop cells from growing and dividing into new cancer cells. Normal cells also have HER2 receptors, so therapies like PERJETA with Herceptin, or PHESGO, may also affect them.
PHESGO is injected under the skin and works in the same way as IV PERJETA and Herceptin to treat HER2+ breast cancer. PHESGO also contains hyaluronidase, a protein that helps the body absorb the two medicines and allows them to be given as a single injection under the skin in just minutes.
PHESGO is a single ~5-minute injection given under the skin,* while PERJETA + Herceptin are given as an intravenous (IV) infusion that can take about 60-150 minutes.
*The first dose is given in ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
In a clinical study, 85% of people preferred PHESGO over PERJETA + Herceptin and the most common reason was less time spent in the clinic.
Patient experiences may vary.
Patient compensated by Genentech.
Watch Jen’s story to hear more about her experience with HER2+ breast cancer and PHESGO.
Most major insurance plans, including private/commercial and public insurance plans, provide coverage for PHESGO*. There may be options available to help you afford your medicine.
*Data current as of 10/2025. (Data on file. Genentech, Inc. MMIT Analysis. HLI Lives Database.) Insurer policies may vary and are subject to change. Individual out-of-pocket cost will vary depending on plan.
Your doctor can answer any questions you have about PHESGO.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.